Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™PRINCETON, N.J., Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol HPN-CTCL-04) comparing HyBryte™ (synthetic hypericin) to Valchlor® (mechlorethamine) has ...

Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024PRINCETON, N.J., Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicen ...

Study DUS-AUBD-01 opens patient enrollmentPRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease."We are pleased to have received FDA cl ...

Core Insights - Soligenix, Inc. is focused on developing treatments for rare diseases with unmet medical needs and has announced recent accomplishments and financial results for Q3 2024 [1] Recent Accomplishments - The Hong Kong Patent Office granted a patent for a novel proprietary process of producing highly purified synthetic hypericin on October 22, 2024 [3] - Lead investigators presented findings on HyBryte™ for CTCL treatment at a European cancer research organization on October 7, 2024 [3] - A partnership with Sterling Pharma Solutions was established to optimize production technology for synthetic hypericin on October 3, 2024 [3] - The European Patent Office granted a similar patent for synthetic hypericin production on September 3, 2024 [3] Clinical Activities and Milestones - The company plans to initiate a Phase 3 placebo-controlled study for HyBryte™ in early-stage CTCL by year-end 2024 [2] - A Phase 2 study for SGX945 in Behçet's disease is set to begin shortly, with top-line results expected in the first half of 2025 [2] - Data from the ongoing Phase 2 study of SGX302 in mild-to-moderate psoriasis is anticipated in the first half of 2025 [2] Financial Results - Soligenix reported no revenue for Q3 2024, compared to $0.1 million in Q3 2023, with revenues primarily from government contracts and grants [4] - The net loss for Q3 2024 was $1.7 million, or ($0.78) per share, consistent with the loss in Q3 2023, which was ($2.56) per share [5] - Research and development expenses increased to $1.0 million in Q3 2024 from $0.8 million in Q3 2023, attributed to costs for new clinical studies [6] - General and administrative expenses decreased to $0.9 million in Q3 2024 from $1.0 million in Q3 2023, mainly due to lower legal and professional fees [7] - As of September 30, 2024, the company's cash position was approximately $9.8 million [7]

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference Princeton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institut ...

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of PsoriasisPRINCETON, N.J., Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". ...

PRINCETON, N.J., Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will be providing a corporate update at the upcoming investor conferences on the dates below. 2024 Maxim Healthcare Virtual Summit, held October 17, 2024. For more information, please refer to the conference website https: ...

U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J., Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has established a partnership agreement with Sterling Pharma Solutions (Sterling) to optimize and implement a commercially viable, scalable production technology ...

PRINCETON, N.J., Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, Inc., will feature Soligenix President and Chief Executive Officer, Christopher J. Schaber, PhD, who will share insight ...

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". The newly issued patent's claims are dire ...